Adlai Nortye Ltd. Sponsored ADR (ANL) has been beaten down lately with too much selling pressure. While the stock has lost 33.1% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentu ...

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will present encouraging preliminary data of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC) at the upcoming American Society of Cancer Oncolo ...

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will present encouraging preliminary data of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC) at the upcoming American Society of Cancer Oncolo ...

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, recently announced that the first patient was dosed in the Phase II clinical trial known as ARTEMIS (Augmenting RadioTherapy in REctal Cancer to Minimise Invasive Surgery). This clinical study evaluates palupiprant (AN0025), a small molecule prostaglandin E ...

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, recently announced that the first patient was dosed in the Phase II clinical trial known as ARTEMIS (Augmenting RadioTherapy in REctal Cancer to Minimise Invasive Surgery). This clinical study evaluates palupiprant (AN0025), a small molecule prostaglandin E ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Adlai Nortye Ltd. Sponsored ADR (ANL) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Adlai Nortye Ltd. Sponsored ADR is one of 1048 individual stocks in the Medical secto ...

ANL股票 - ANL是医疗部门的一员，拥有1051只个股，目前的Zacks部门排名为第3位[2] - ANL今年迄今为止涨幅约为50.7%，而医疗股平均涨幅为1.2%，显示ANL在今年的表现优于同行[4] - ANL属于医疗-生物医学和遗传学行业，该行业包括506只个股，目前在Zacks行业排名中位列第69位[7] Elevance Health股票 - Elevance Health（ELV）是另一只医疗股，今年迄今涨幅为13.2%[5] - Elevance Health的共识每股收益预估今年增长了0.2%，目前Zacks排名为2（买入）[6] - Elevance Health属于医疗服务行业，该行业目前排名第80位，今年迄今上涨了5%[8] 投资建议 - 投资者应继续关注ANL和Elevance Health，这两只股票将继续保持良好表现[9]

公司运营 - 公司的日常运营主要通过位于美国和中国大陆的子公司进行[12] - 美国和香港的子公司可以无限制地向公司提供资金[14] - 中国的货币兑换限制可能限制公司将人民币自由兑换为美元用于未来业务活动[15] - 公司在2021年至2023年期间进行了资本贡献和内部贷款[17] 法律和风险 - 公司面临着中国法律和法规带来的各种法律和运营风险[21] 业务依赖 - 公司的业务主要依赖于临床前和临床药物候选者的成功[25] - 公司将依赖药物候选者的成功发展、获得监管批准和商业化[42] 合作风险 - 公司与第三方合作可能会增加长期支出、发行股票、或干扰管理和业务[50] - 与第三方合作可能导致控制权转移、预期收益未达成、合作成本增加[50] - 公司依赖第三方进行临床开发活动，可能延迟或限制药物候选品的未来发展或获得监管批准[51] 知识产权风险 - 公司和商业伙伴获得和维护药物候选品和技术的知识产权保护对成功至关重要[59] - 公司拥有和许可的专利和专利申请可能会面临优先权争议、发明人争议和类似诉讼[61] - 公司可能面临第三方专利侵权或其他知识产权侵犯的风险[62] 临床试验风险 - 公司可能无法在临床试验中招募足够数量的患者[84] - 不良事件可能导致临床试验中断、延迟或停止[87] - 临床试验的中间、初步数据可能会发生变化[89] 生产和质量风险 - 我们依赖第三方制造商来生产药物候选品[98] - 制造过程中可能出现各种问题，如设备故障、原材料质量低下等[100] - 产品质量问题可能导致产品报废，增加成本[101] 市场和竞争风险 - 公司可能面临激烈竞争和技术变革，竞争对手可能开发出更先进或更有效的疗法[109] - 我们的竞争对手可能比我们更快获得监管批准，并更有效地销售和营销他们的产品[110] 财务风险 - 公司自2021年至2023年分别录得净亏损为5,670万美元、5,880万美元和1.049亿美元[140] - 公司预计未来将继续承担重大支出和亏损，特别是在推进药物候选品的临床开发、启动其他临床试验、寻求药物候选品的监管批准等方面[140] - 公司自2021年至2023年的经营活动中录得净现金流出分别为3,000万美元、4,320万美元和5,670万美元[142] 其他风险 - 公司可能面临自然灾害、战争、恐怖袭击等不可预测因素的风险[158] - 公司的国际业务可能受到各种贸易限制的影响，包括经济制裁和出口管制[157]

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Archie Tse as Head of Research & Development, reporting to Mr. Carsten Lu, CEO and Chairman of Adlai Nortye, effective March 29th, 2024. Dr. Tse, M.D. & Ph.D. earned Doctor of Medicine and Doctor of Biochemistry and M ...